Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Cash & Equivalents (2016 - 2025)

Sanofi's Cash & Equivalents history spans 10 years, with the latest figure at $8.9 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 12.09% year-over-year to $8.9 billion; the TTM value through Dec 2025 reached $8.9 billion, up 12.09%, while the annual FY2025 figure was $8.7 billion, 7.42% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $8.9 billion at Sanofi, up from $8.0 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $13.0 billion in Q4 2022 and bottomed at $8.0 billion in Q4 2024.
  • The 4-year median for Cash & Equivalents is $10.2 billion (2021), against an average of $10.4 billion.
  • The largest annual shift saw Cash & Equivalents plummeted 30.37% in 2021 before it rose 12.48% in 2022.
  • A 4-year view of Cash & Equivalents shows it stood at $11.6 billion in 2021, then increased by 12.48% to $13.0 billion in 2022, then crashed by 38.81% to $8.0 billion in 2024, then increased by 12.09% to $8.9 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Cash & Equivalents are $8.9 billion (Q4 2025), $8.0 billion (Q4 2024), and $13.0 billion (Q4 2022).